News-Excellence achieved through unity and diversity. Convergence and condensation result in crystallization.

Excellence achieved through unity and diversity. Convergence and condensation result in crystallization.

Homepage > News
16 2026-02

Spring Festival Reunion Wine: Health Never Stops! Jingjing Pharmaceutical uses professional ingredients to protect liver health.

“Raising a glass to invite friends and relatives, gathering together to celebrate the New Year” – the tradition of drinking during the Spring Festival has long been integrated into folk culture. From the ancient Jiaobai wine, which was used for praying for blessings and warding off evil spirits, to the modern gatherings that serve to strengthen family bonds, alcohol plays an indispensable role in creating a festive atmosphere. However, the frequent drinking also makes liver health a major concern for many people. Traditional health concepts emphasize the importance of…

16 2026-02

Jingjing Pharmaceutical nourishes its original aspiration with the festive atmosphere of the New Year and crafts brilliant chapters with craftsmanship

Spring returns to China, and a new year begins. As red lanterns adorn the streets and alleys, and the fragrance of ink from Spring Festival couplets permeates the air, the "Spring Festival"—this celebration that carries the millennia-old sentiments of the Chinese nation—unfolds a tapestry of warmth and harmony among families. The Spring Festival embodies the warmth of reunion, engraves the original intention of perseverance, and also nurtures...

09 2026-02

Jingjing Pharmaceutical's Rulibactam: A new hope in the fight against superbugs

When severe infections reach a desperate situation where there are no drugs available for treatment, “superbugs”—multidrug-resistant bacteria—become invisible killers that devour health. They gradually break through the defenses of traditional antibiotics, leaving antimicrobial therapy in a dilemma of having run out of options. The emergence of “Rilabactam” is like a ray of dawn piercing through the haze, bringing new hope and possibilities...

09 2026-02

The Era of Multidrug-Resistant Bacteria: The Clinical Necessity and Value of Phosphomycin Sodium in Combination Therapy

Currently, infections caused by multi-drug resistant organisms (MDR) such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) have become significant challenges in clinical treatment. According to the WHO, such infections are responsible for approximately 1.27 million deaths each year. Fosfomycin sodium, due to its unique mechanism of action, plays a crucial role in combination therapies...

05 2026-02

Copy services build a reputation; we work together towards a successful future. Jingjing Pharmaceutical offers comprehensive and considerate services across the entire chain, accompanying you as you delve deeper into the pharmaceutical industry!

Having been deeply involved in the pharmaceutical industry for 20 years, Jingjing Pharmaceutical has always adhered to the philosophy of "harmony and excellence, combining to form a crystal." It regards research and development innovation as the core driving force for corporate growth, establishing a research and development system that covers multiple fields and combines professionalism with innovation. With its technical expertise, the company lays a solid foundation for cooperation with its clients, injecting strong momentum into the cause of health.

03 2026-02

Jingjing Pharmaceutical — Focusing on research and development as its core, products as its foundation, and service as its essence, it empowers the new development of the industry.

When health becomes an essential need of the times, and innovation becomes a consensus in the industry, Jingjing Pharmaceutical has been diligently working for 20 years, adhering to its original vision with craftsmanship and embarking on new journeys through innovation. Based in the biomanufacturing industry, Jingjing Pharmaceutical operates with the core philosophy of “harmony among all, refinement through unity,” and has built a tripartite core competitiveness that integrates research and development, products, and services.

03 2026-02

Technology for soul-casting, service for empowerment: The in-depth development path of Jingjing Pharmaceutical's CDMO and CMO businesses and a promising future

In the wave of the global pharmaceutical industry's transformation towards "innovation, sustainability, and integration," CDMOs (Contract Development and Manufacturing Organizations) and CMOs (Contract Manufacturing Organizations), as core hubs of the pharmaceutical supply chain, play a vital role in connecting drug research and development with commercial production, thus becoming a significant force in driving the efficient development of the pharmaceutical industry. Domestic characteristics and original...

01 2026-02

Antibiotic Competition: Jingjing Pharmaceutical's Fosfomycin Sodium – Low Resistance, High Safety, Broad Spectrum Coverage – A New Choice for Antibacterial Treatment

Fosfomycin sodium, as a broad-spectrum antibiotic, operates by inhibiting the early synthesis of the bacterial cell wall. This mechanism differs from the targets of other mainstream antimicrobial drugs such as β-lactams, aminoglycosides, and quinolones. This uniqueness endows it with significant advantages in terms of its antibacterial spectrum, resistance profile, and safety profile. The following information relates to its comparison with similar drugs in the same class/clinical setting...

01 2026-02

Jingjing Pharmaceutical AKG – How to help you fight aging and reverse the effects of time!

What is AKG? The “core component” of the cellular energy factory AKG (Alpha-Ketoglutarate) is a key intermediate metabolite in the tricarboxylic acid cycle (TCA cycle, also known as the Krebs cycle). Simply put, it is an essential “hub molecule” in the process by which cells convert food into energy. If…

01 2026-02

Jingjing Pharmaceutical Rulibactam vs Traditional β-Lactamase Inhibitors – Stable Structure, No Drug Resistance, Broad Enzyme Inhibition Spectrum

Rulibactam, a product of Jingjing Pharmaceutical, has the following advantages compared to traditional β-lactamase inhibitors: it has a stable structure, does not induce drug resistance, and has a broad spectrum of enzyme inhibition. Rulibactam is a novel β-lactamase inhibitor with a DBO (Dibenzoyl-Oxazoline) structure. Its key characteristic is the absence of a β-lactam ring structure, which means it must be used in combination with imipenem or cilastatin to exert its antibacterial effect. This drug is primarily used for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.